The present invention features interferon-free therapies for the treatment of HCV. Preferably the treatment is over a shorter duration such as no more than 12 weeks. In one aspect the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example the therapies comprise administering to the subject effective amounts of therapeutic agent 1 therapeutic agent 2 (or therapeutic agent 3) an inhibitor of cytochrome P450 (e.g. rito...

The present invention provides genetic markers and biomarkers that are associated with anemia induced by ribavirin therapy. The genetic markers are located in the ITPA gene and elsewhere on human chromosome 20 and the biomarkers are low ITPA activity phenotypes. These markers of ribavirin-induced anemia are useful inter alia to identify patients who are least likely to develop anemia upon treatment with ribavirin pharmaceutical compositions and drug products in methods of treating patients havin...

The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions dosages kits and packs.

The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably the treatment is over a shorter duration of treatment such as no more than 12 weeks. In one aspect the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example the therapies comprise administering to a subject an effective amounts of therapeutic agent 1 therapeutic agent 2 (or therapeutic age...

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g...

The present invention features interferon-free therapies for the treatment of HCV. Preferably the treatment is over a shorter duration such as no more than 12 weeks. In one aspect the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example the therapies comprise administering to the subject effective amounts of therapeutic agent 1 therapeutic agent 2 (or therapeutic agent 3) an inhibitor of cytochrome P450 (e.g. rito...

Claimed and disclosed is a new use for a previously approved drug: erythropoietin. The present invention teaches using Erythropoetin to treat anemia caused by the combined treatment of Ribavirin and alpha-interferon. Erythropoetin has previously been approved for the treatment of anemia caused by cancer chemotherapy, renal failure and HIV. It has not been used for anemia caused by ribavirin. Ribavirin is part of a two-drug regimen now used to treat hepatitis C along with alpha interferon. The pr...

Claimed and disclosed is a new use for a previously approved drug: erythropoietin. The present invention teaches using Erythropoetin to treat anemia caused by the combined treatment of Ribavirin and alpha-interferon. Erythropoetin has previously been approved for the treatment of anemia caused by cancer chemotherapy renal failure and HIV. It has not been used for anemia caused by ribavirin. Ribavirin is part of a two-drug regimen now used to treat hepatitis C along with alpha interferon. The pri...